Journal article

A Randomized, Multicenter, Open-Label, Blinded End Point, Phase 2, Feasibility, Efficacy, and Safety Trial of Preoperative Microvascular Protection in Patients Undergoing Major Abdominal Surgery

Fumitaka Yanase, Shervin H Tosif, Leonid Churilov, Ken Yee, Rinaldo Bellomo, Kerry Gunn, Chang Kim, Camilla Krizhanovskii, Robert G Hahn, Bernhard Riedel, Laurence Weinberg



BACKGROUND: The endothelial glycocalyx, a carbohydrate-rich layer coating all endothelial surfaces, plays a fundamental role in the function of microcirculation. The primary aim of this study was to evaluate the feasibility of using dexamethasone and albumin to protect the endothelial glycocalyx in patients undergoing abdominal surgery. Secondary and exploratory outcomes included efficacy and safety. METHODS: We conducted a multicenter, open-label, blinded end point, phase 2, randomized trial. Patients undergoing colorectal, pancreas, or liver surgery were recruited and randomized to receive either intravenous dexamethasone (16 mg) and 20% albumin (100 mL) at induction of anesthesia, then 20..

View full abstract


Funding Acknowledgements

This study was supported by a CSL Behring Australia and New Zealand College of Anaesthetists Grant and an Auckland District Health Board A+ Trust Grant. All aspects of the study design, execution, data collection, and analysis were conducted independently of CSL Behring or any other industry.